April 15, 2024
A key Japanese health ministry panel will discuss whether to grant orphan drug designations for three compounds on April 26, including cannabidiol, a cannabis-derived anti-seizure treatment known as Epidiolex overseas. Cannabidiol, being developed by Jazz Pharmaceuticals, will be discussed for...read more